Addressing Benzodiazepine Use in OTPs

Benzodiazepines significantly enhance the action of other Central Nervous System (CNS) depressant medications including methadone and buprenorphine. On their own, benzodiazepines have a broad safety profile but in combination with opioids in particular, the risk of sedation and respiratory depression increases significantly.   Patients with a history of addiction are at much higher risk for benzodiazepine misuse and dependence; therefore, benzodiazepines are not the ideal treatment for insomnia or anxiety in most cases.  Tolerance to benzodiazepine-induced euphoria and sedation develops quickly, and withdrawal can be life threatening.  Abuse liability of specific benzodiazepines varies depending on pharmacokinetic properties, rate of absorption, metabolism, intrinsic activity and elimination half-life.  There are few clinical situations where benzodiazepines may be appropriate for short-term use in methadone or buprenorphine treated patients.  Despite the known increased risks of overdose and misuse, opioid dependent patients often access these prescriptions.

Worldwide, 18-50% of patients receiving methadone in Opioid Treatment programs (OTPs) are dependent on benzodiazepines. [i] Benzodiazepine use among patients in opioid agonist medication assisted therapy is linked to poorer outcomes; the combination with opioid agonists poses significant risks for morbidity and mortality.  There are few published articles that offer useful guidance for management of benzodiazepines in OTPs. As a result, treatment protocols and clinical practice vary. In spite of the gap in the literature, care should be taken with patients admitted to opioid agonist treatment with either licit or illicit benzodiazepine use.  Treatment of opioid use disorder with medications should not be discouraged or delayed, but the risks of ongoing benzodiazepine use should be taken seriously and interventions guided accordingly.

The purpose of this document is to offer guidance instead of restrictive procedures to assist programs in treating patients in OTPs who use benzodiazepines. [ii] [iii] [iv] [v] [vi] [vii] [viii] [ix] [x] [xi]

  • OTPs should be diligent and use caution when admitting patients taking benzodiazepines or any other sedating medications.  CNS depressant use is not an absolute contraindication and such use should be addressed in treatment.  Adjustments in induction procedures and additional monitoring may be required.  Therefore, benzodiazepine using individuals should not be categorically denied admission to OTPs.
  • Education and the provision of educational materials of the combined risks of benzodiazepine, prescribed or illicit sedatives, opioid analgesics and alcohol use should be a routine part of orientation to opioid agonist treatment.   Documentation that this was reviewed with the patient and should be entered in the record.
  • Benzodiazepines are associated with significant risk for patients in opioid agonist treatment therefore, not the treatment of choice for anxiety.   Treatment plans should be developed on admission, or when indicated during treatment to address benzodiazepine use.   In the great majority of cases, cessation of benzodiazepines is preferred.  In some cases, admission to an OTP may be delayed until a taper/detox is completed, often requiring more monitoring in a higher level of care.  In others, gradually tapering off a prescribed benzodiazepine or decreasing to the lowest effective dose is appropriate.  A gradual taper from opioid agonist treatment can be therapeutic, combined with continued attempts to help patients address benzodiazepine use and decrease risks, with a goal of keeping them in treatment if possible.  However, continued refusal to address benzodiazepine use on the part of the patient may be grounds for discharge from an OTP.
  • Patients who are prescribed or illicitly use benzodiazepines should be considered at risk for adverse reactions including overdose and death, therefore may require additional safety monitoring.  Prohibiting admission or creating excessive access barriers can pose even greater threats to morbidity and mortality.    A balance of providing care, medications and appropriate oversight and monitoring is necessary to successfully achieve desired clinical outcomes.
    • The Prescription Monitoring Drug Program (PDMP) in your State should be checked on admission and at regular intervals throughout the patient’s treatment.
    • Cooperative partnerships with prescribers allow for the exchange of information about medication use concerns and the development of a cohesive treatment plan.  A signed 42 CFR Part 2 compliant release of information is advised for patients in OTPs receiving prescribed benzodiazepines and other sedating medications for coordination of care between the OTP and prescribing clinician.     Admission to an OTP may be denied if patients do not consent to coordination of care with outside prescribing providers.
    • Program medical providers should collaborate with the prescribers so they are aware of the patient’s admission to an OTP, the concerns of concurrent use of benzodiazepines, and to plan for coordination of care.  To improve safety and minimize risks, prescribers should be advised to decrease the benzodiazepine dose to the lowest effective dose, and consider alternative medications and non-pharmacologic treatments to address anxiety or insomnia.
    • If a patient is sedated, holding or decreasing the methadone or buprenorphine dose is appropriate until further evaluation is completed.
    • Taking steps towards further integration of opioid treatment with mental health treatment either in specialty or primary care is essential for managing OTP patients’ chronic health conditions.  OTPs need to increase their ability to provide directly or collaborate more thoroughly, with psychiatric providers.   If unable to integrate those services in-house, then more emphasis needs to be placed on partnerships/ collaborations for providing the mental health care.
  • Diversion of prescribed medications is a risk for any patient with a substance use disorder.  Care should be taken to ensure that patients are taking the medications prescribed and not diverting or supplementing with illicit drugs.
    • Toxicology screening should test for prescribed and illicit benzodiazepines.
    • Toxicology screening varies and some benzodiazepines are not reliably detected. Confirming whether the benzodiazepine is taken daily or on an as needed basis is important for evaluating accuracy of unexpected negative toxicology results.
    • Confirmatory testing should be considered for suspicion of misuse or substitution.
    • Routine PMDP checks should be done for suspicion of doctor shopping.
  • There is no evidence to support dose limitations or arbitrary caps of methadone or buprenorphine as a strategy to address benzodiazepine use in opioid agonist treated patients.  The OTP physician and prescribing clinician should individually determine the appropriate dose and treatment plan for the patient according to the risk profile, observed behavior and treatment response.

There is strong evidence that the use of benzodiazepines and other sedating medications combined with methadone or buprenorphine pose safety risks.  OTPs should work to ensure that patients considering controlled substances have had quality diagnostic evaluations to optimize diagnostic accuracy, and ensure that safer medication options have been considered.     Careful monitoring and coordination of care that is respectful but not capricious or punitive is essential to ensure access to safe, effective and individualized care for patients in OTPs.

Benzodiazepines significantly enhance the action of other Central Nervous System (CNS) depressant medications including methadone and buprenorphine. On their own, benzodiazepines have a broad safety profile but in combination with opioids in particular, the risk of sedation and respiratory depression increases significantly.   Patients with a history of addiction are at much higher risk for benzodiazepine misuse and dependence; therefore, benzodiazepines are not the ideal treatment for insomnia or anxiety in most cases.  Tolerance to benzodiazepine-induced euphoria and sedation develops quickly, and withdrawal can be life threatening.  Abuse liability of specific benzodiazepines varies depending on pharmacokinetic properties, rate of absorption, metabolism, intrinsic activity and elimination half-life.  There are few clinical situations where benzodiazepines may be appropriate for short-term use in methadone or buprenorphine treated patients.  Despite the known increased risks of overdose and misuse, opioid dependent patients often access these prescriptions.

Worldwide, 18-50% of patients receiving methadone in Opioid Treatment programs (OTPs) are dependent on benzodiazepines. [i] Benzodiazepine use among patients in opioid agonist medication assisted therapy is linked to poorer outcomes; the combination with opioid agonists poses significant risks for morbidity and mortality.  There are few published articles that offer useful guidance for management of benzodiazepines in OTPs. As a result, treatment protocols and clinical practice vary. In spite of the gap in the literature, care should be taken with patients admitted to opioid agonist treatment with either licit or illicit benzodiazepine use.  Treatment of opioid use disorder with medications should not be discouraged or delayed, but the risks of ongoing benzodiazepine use should be taken seriously and interventions guided accordingly.

The purpose of this document is to offer guidance instead of restrictive procedures to assist programs in treating patients in OTPs who use benzodiazepines. [ii] [iii] [iv] [v] [vi] [vii] [viii] [ix] [x] [xi]

  • OTPs should be diligent and use caution when admitting patients taking benzodiazepines or any other sedating medications.  CNS depressant use is not an absolute contraindication and such use should be addressed in treatment.  Adjustments in induction procedures and additional monitoring may be required.  Therefore, benzodiazepine using individuals should not be categorically denied admission to OTPs.
  • Education and the provision of educational materials of the combined risks of benzodiazepine, prescribed or illicit sedatives, opioid analgesics and alcohol use should be a routine part of orientation to opioid agonist treatment.   Documentation that this was reviewed with the patient and should be entered in the record.
  • Benzodiazepines are associated with significant risk for patients in opioid agonist treatment therefore, not the treatment of choice for anxiety.   Treatment plans should be developed on admission, or when indicated during treatment to address benzodiazepine use.   In the great majority of cases, cessation of benzodiazepines is preferred.  In some cases, admission to an OTP may be delayed until a taper/detox is completed, often requiring more monitoring in a higher level of care.  In others, gradually tapering off a prescribed benzodiazepine or decreasing to the lowest effective dose is appropriate.  A gradual taper from opioid agonist treatment can be therapeutic, combined with continued attempts to help patients address benzodiazepine use and decrease risks, with a goal of keeping them in treatment if possible.  However, continued refusal to address benzodiazepine use on the part of the patient may be grounds for discharge from an OTP.
  • Patients who are prescribed or illicitly use benzodiazepines should be considered at risk for adverse reactions including overdose and death, therefore may require additional safety monitoring.  Prohibiting admission or creating excessive access barriers can pose even greater threats to morbidity and mortality.    A balance of providing care, medications and appropriate oversight and monitoring is necessary to successfully achieve desired clinical outcomes.
    • The Prescription Monitoring Drug Program (PDMP) in your State should be checked on admission and at regular intervals throughout the patient’s treatment.
    • Cooperative partnerships with prescribers allow for the exchange of information about medication use concerns and the development of a cohesive treatment plan.  A signed 42 CFR Part 2 compliant release of information is advised for patients in OTPs receiving prescribed benzodiazepines and other sedating medications for coordination of care between the OTP and prescribing clinician.     Admission to an OTP may be denied if patients do not consent to coordination of care with outside prescribing providers.
    • Program medical providers should collaborate with the prescribers so they are aware of the patient’s admission to an OTP, the concerns of concurrent use of benzodiazepines, and to plan for coordination of care.  To improve safety and minimize risks, prescribers should be advised to decrease the benzodiazepine dose to the lowest effective dose, and consider alternative medications and non-pharmacologic treatments to address anxiety or insomnia.
    • If a patient is sedated, holding or decreasing the methadone or buprenorphine dose is appropriate until further evaluation is completed.
    • Taking steps towards further integration of opioid treatment with mental health treatment either in specialty or primary care is essential for managing OTP patients’ chronic health conditions.  OTPs need to increase their ability to provide directly or collaborate more thoroughly, with psychiatric providers.   If unable to integrate those services in-house, then more emphasis needs to be placed on partnerships/ collaborations for providing the mental health care.
  • Diversion of prescribed medications is a risk for any patient with a substance use disorder.  Care should be taken to ensure that patients are taking the medications prescribed and not diverting or supplementing with illicit drugs.
    • Toxicology screening should test for prescribed and illicit benzodiazepines.
    • Toxicology screening varies and some benzodiazepines are not reliably detected. Confirming whether the benzodiazepine is taken daily or on an as needed basis is important for evaluating accuracy of unexpected negative toxicology results.
    • Confirmatory testing should be considered for suspicion of misuse or substitution.
    • Routine PMDP checks should be done for suspicion of doctor shopping.
  • There is no evidence to support dose limitations or arbitrary caps of methadone or buprenorphine as a strategy to address benzodiazepine use in opioid agonist treated patients.  The OTP physician and prescribing clinician should individually determine the appropriate dose and treatment plan for the patient according to the risk profile, observed behavior and treatment response.

There is strong evidence that the use of benzodiazepines and other sedating medications combined with methadone or buprenorphine pose safety risks.  OTPs should work to ensure that patients considering controlled substances have had quality diagnostic evaluations to optimize diagnostic accuracy, and ensure that safer medication options have been considered.     Careful monitoring and coordination of care that is respectful but not capricious or punitive is essential to ensure access to safe, effective and individualized care for patients in OTPs.

 

Visit the aatod conference website for more details…www.aatodconference.com.

@aatod1984
  • View the latest #aatod2024 Conference Video Message from the Host Committee Chair, Katro Henderson. We look forward to seeing you next month in Las Vegas for the world’s premier training conference event for the Treatment of Opioid Use Disorder. #OUD #somuchmorethanmedication

https://youtu.be/i6u3qUS95jU
  • 💻 Access the 3/27 SAMHSA Webinar Recording on 42 CFR Part 8, Clinical ➡️ bit.ly/3TIEZdW.

#ICYMI This comprehensive webinar provided an overview of the rule changes and provided a discussion with SAMHSA regarding the implications of the changes.
  • 💻 Webinar Recording is Now Available
AATOD is pleased to share the March 20th SAMHSA Webinar Recording on 42 CFR Part 8, Administrative.  We encourage you to view this recording to assist you in determining how you will need to prepare for full implementation of these regulations. 

➡ https://youtu.be/pgWZUpDhi94?si=obomo4LXRIwJPiC8
  • 3/28 Expanding Access to #Methadone in Correctional Facilities will focus on opportunities to expand access to methadone in correctional facilities, including recent developments with the SAMHSA 2024 final rule on the use of methadone.

Register ➡️ bit.ly/3Vz1RPE
  • Invitation to SAMHSA Webinars on 42 CFR Part 8 💻 

On February 2, 2024, the final rule for 42 CFR Part 8 was published. The effective date for these regulations is April 2, 2024, with an implementation date of October 2, 2024. 

In preparation for implementation of the revisions, SAMHSA will provide two preliminary webinars for OTPs.  The first will focus on administrative areas; the second will focus more on clinical content. These will be held on March 20th (from 2-3pm EST) and March 27th, 2024 (from 2- 3pm EST).  

REGISTER ➡ https://conta.cc/3TF9CSQ

View the final rule ➡ https://lnkd.in/e_iu-AtG.

There will be an opportunity to receive an overview of the rule changes and discuss with SAMHSA the implications of the changes. 

We encourage you to attend these important meetings to assist you in determining how you will need to prepare for full implementation of these regulations. 

This webinar series will be moderated by Mark W. Parrino, MPA (AATOD President). Speakers include Yngvild Olsen, MD, MPH (Director - CSAT), Robert Baillieu, MD, MPH, FAAFP (Physician and Senior Advisor - SAMHSA/CSAT, and Patti Juliana, PhD, LCSW
(Director - CSAT’s Division of Pharmacologic Therapies).

The presentations will be followed by Q&A, and these webinars will become available to the public for On-Demand viewing via the AATOD website. Certificates of Attendance will be provided per request.
  • Don’t miss out on the chance to show your support, share your products/services and secure your sponsorship at the AATOD 2024 Conference, �The world’s premier training conference event for the Treatment of Opioid Use Disorder. #aatod2024

The 2024 AATOD Conference will attract over 1,600 physicians, social workers, nurses, counselors, program administrators, executive directors, and other treatment providers from many countries. The registrants are decision-makers with purchasing power for their treatment centers and are looking for new products, services, and information to improve their patient treatment.

To become an exhibitor today —> https://bit.ly/48ZKMRX
  • TREATING OPIOID USE DISORDER: SO MUCH MORE THAN MEDICATION

💻 View the latest Conference Video Message from AATOD's President, Mark W. Parrino bit.ly/48y815w,
for the most up-to-date details regarding the upcoming #aatod2024 Conference -
The world's premier training conference event for the treatment of Opioid Use Disorder. #OUD 

Registration ➡️ www.aatodconference.com
  • TREATING OPIOID USE DISORDER: SO MUCH MORE THAN MEDICATION #aatod2024

TODAY is the last day to take advantage of the discounted registration rate. #aatod2024 is the world’s premier training conference event for the treatment of #OUD.

For registration and hotel information ➡️ bit.ly/3Ue57Q6.

We look forward to seeing you in Las Vegas!
  • #aatod2024 Conference Update. Comprehensive Listing/Descriptions of Workshops, Posters, and Hot Topic Roundtable Conference Sessions are now available ➡️ http://bit.ly/3Ue57Q6.

The workshop committee is pleased to present a dynamic workshop lineup that includes extremely rich and diverse educational content for all disciplines. You will hear from experts who will share the latest research and developments relating to opioid use disorders and treatment. The workshop lineup will include state of the art information on diverse areas of focus such as patient care and best practices, building community partnerships and collaborations, public policy and regulatory changes, workforce development, quality assurance, and financial reimbursement. There will be workshops that focus on emerging treatment trends and developments such as the fentanyl epidemic, mobile opioid treatment programs, regulatory changes, expansion of treatment services in rural areas, integrating treatment with the corrections systems, and integrating harm reduction initiatives. For those newer to the field or those who want a refresher on the basics, we have once again included a “Foundations” track which will include selections on the fundamentals of medication assisted treatment.

The conference will continue to be the world’s premier training and education event for the treatment of opioid use disorders.  We hope to see you in Las Vegas!
  • Patient access to OTPs saves lives every day.

AATOD has been working with policymakers and regulatory authorities to increase access to opioid treatment programs (OTPs) though the expansion of mobile vans and Medication Assisted Treatment in correctional facilities in the United States. 

Please support AATOD's mission by making an online donation ➡️ https://bit.ly/3uDOeDC #givingtuesday
View the latest #aatod2024 Conference Video Message from the Host Committee Chair, Katro Henderson. We look forward to seeing you next month in Las Vegas for the world’s premier training conference event for the Treatment of Opioid Use Disorder. #OUD #somuchmorethanmedication

https://youtu.be/i6u3qUS95jU
View the latest #aatod2024 Conference Video Message from the Host Committee Chair, Katro Henderson. We look forward to seeing you next month in Las Vegas for the world’s premier training conference event for the Treatment of Opioid Use Disorder. #OUD #somuchmorethanmedication https://youtu.be/i6u3qUS95jU
5 days ago
View on Instagram |
1/10
💻 Access the 3/27 SAMHSA Webinar Recording on 42 CFR Part 8, Clinical ➡️ bit.ly/3TIEZdW.

#ICYMI This comprehensive webinar provided an overview of the rule changes and provided a discussion with SAMHSA regarding the implications of the changes.
💻 Access the 3/27 SAMHSA Webinar Recording on 42 CFR Part 8, Clinical ➡️ bit.ly/3TIEZdW. #ICYMI This comprehensive webinar provided an overview of the rule changes and provided a discussion with SAMHSA regarding the implications of the changes.
1 week ago
View on Instagram |
2/10
💻 Webinar Recording is Now Available
AATOD is pleased to share the March 20th SAMHSA Webinar Recording on 42 CFR Part 8, Administrative.  We encourage you to view this recording to assist you in determining how you will need to prepare for full implementation of these regulations. 

➡ https://youtu.be/pgWZUpDhi94?si=obomo4LXRIwJPiC8
💻 Webinar Recording is Now Available AATOD is pleased to share the March 20th SAMHSA Webinar Recording on 42 CFR Part 8, Administrative. We encourage you to view this recording to assist you in determining how you will need to prepare for full implementation of these regulations. ➡ https://youtu.be/pgWZUpDhi94?si=obomo4LXRIwJPiC8
2 weeks ago
View on Instagram |
3/10
3/28 Expanding Access to #Methadone in Correctional Facilities will focus on opportunities to expand access to methadone in correctional facilities, including recent developments with the SAMHSA 2024 final rule on the use of methadone.

Register ➡️ bit.ly/3Vz1RPE
3/28 Expanding Access to #Methadone in Correctional Facilities will focus on opportunities to expand access to methadone in correctional facilities, including recent developments with the SAMHSA 2024 final rule on the use of methadone. Register ➡️ bit.ly/3Vz1RPE
3 weeks ago
View on Instagram |
4/10
Invitation to SAMHSA Webinars on 42 CFR Part 8 💻 

On February 2, 2024, the final rule for 42 CFR Part 8 was published. The effective date for these regulations is April 2, 2024, with an implementation date of October 2, 2024. 

In preparation for implementation of the revisions, SAMHSA will provide two preliminary webinars for OTPs.  The first will focus on administrative areas; the second will focus more on clinical content. These will be held on March 20th (from 2-3pm EST) and March 27th, 2024 (from 2- 3pm EST).  

REGISTER ➡ https://conta.cc/3TF9CSQ

View the final rule ➡ https://lnkd.in/e_iu-AtG.

There will be an opportunity to receive an overview of the rule changes and discuss with SAMHSA the implications of the changes. 

We encourage you to attend these important meetings to assist you in determining how you will need to prepare for full implementation of these regulations. 

This webinar series will be moderated by Mark W. Parrino, MPA (AATOD President). Speakers include Yngvild Olsen, MD, MPH (Director - CSAT), Robert Baillieu, MD, MPH, FAAFP (Physician and Senior Advisor - SAMHSA/CSAT, and Patti Juliana, PhD, LCSW
(Director - CSAT’s Division of Pharmacologic Therapies).

The presentations will be followed by Q&A, and these webinars will become available to the public for On-Demand viewing via the AATOD website. Certificates of Attendance will be provided per request.
Invitation to SAMHSA Webinars on 42 CFR Part 8 💻 On February 2, 2024, the final rule for 42 CFR Part 8 was published. The effective date for these regulations is April 2, 2024, with an implementation date of October 2, 2024. In preparation for implementation of the revisions, SAMHSA will provide two preliminary webinars for OTPs.  The first will focus on administrative areas; the second will focus more on clinical content. These will be held on March 20th (from 2-3pm EST) and March 27th, 2024 (from 2- 3pm EST).  REGISTER ➡ https://conta.cc/3TF9CSQ View the final rule ➡ https://lnkd.in/e_iu-AtG. There will be an opportunity to receive an overview of the rule changes and discuss with SAMHSA the implications of the changes. We encourage you to attend these important meetings to assist you in determining how you will need to prepare for full implementation of these regulations. This webinar series will be moderated by Mark W. Parrino, MPA (AATOD President). Speakers include Yngvild Olsen, MD, MPH (Director - CSAT), Robert Baillieu, MD, MPH, FAAFP (Physician and Senior Advisor - SAMHSA/CSAT, and Patti Juliana, PhD, LCSW (Director - CSAT’s Division of Pharmacologic Therapies). The presentations will be followed by Q&A, and these webinars will become available to the public for On-Demand viewing via the AATOD website. Certificates of Attendance will be provided per request.
4 weeks ago
View on Instagram |
5/10
Don’t miss out on the chance to show your support, share your products/services and secure your sponsorship at the AATOD 2024 Conference, �The world’s premier training conference event for the Treatment of Opioid Use Disorder. #aatod2024

The 2024 AATOD Conference will attract over 1,600 physicians, social workers, nurses, counselors, program administrators, executive directors, and other treatment providers from many countries. The registrants are decision-makers with purchasing power for their treatment centers and are looking for new products, services, and information to improve their patient treatment.

To become an exhibitor today —> https://bit.ly/48ZKMRX
Don’t miss out on the chance to show your support, share your products/services and secure your sponsorship at the AATOD 2024 Conference, �The world’s premier training conference event for the Treatment of Opioid Use Disorder. #aatod2024 The 2024 AATOD Conference will attract over 1,600 physicians, social workers, nurses, counselors, program administrators, executive directors, and other treatment providers from many countries. The registrants are decision-makers with purchasing power for their treatment centers and are looking for new products, services, and information to improve their patient treatment. To become an exhibitor today —> https://bit.ly/48ZKMRX
1 month ago
View on Instagram |
6/10
TREATING OPIOID USE DISORDER: SO MUCH MORE THAN MEDICATION

💻 View the latest Conference Video Message from AATOD's President, Mark W. Parrino bit.ly/48y815w,
for the most up-to-date details regarding the upcoming #aatod2024 Conference -
The world's premier training conference event for the treatment of Opioid Use Disorder. #OUD 

Registration ➡️ www.aatodconference.com
TREATING OPIOID USE DISORDER: SO MUCH MORE THAN MEDICATION 💻 View the latest Conference Video Message from AATOD's President, Mark W. Parrino bit.ly/48y815w, for the most up-to-date details regarding the upcoming #aatod2024 Conference - The world's premier training conference event for the treatment of Opioid Use Disorder. #OUD Registration ➡️ www.aatodconference.com
2 months ago
View on Instagram |
7/10
TREATING OPIOID USE DISORDER: SO MUCH MORE THAN MEDICATION #aatod2024

TODAY is the last day to take advantage of the discounted registration rate. #aatod2024 is the world’s premier training conference event for the treatment of #OUD.

For registration and hotel information ➡️ bit.ly/3Ue57Q6.

We look forward to seeing you in Las Vegas!
TREATING OPIOID USE DISORDER: SO MUCH MORE THAN MEDICATION #aatod2024 TODAY is the last day to take advantage of the discounted registration rate. #aatod2024 is the world’s premier training conference event for the treatment of #OUD. For registration and hotel information ➡️ bit.ly/3Ue57Q6. We look forward to seeing you in Las Vegas!
3 months ago
View on Instagram |
8/10
#aatod2024 Conference Update. Comprehensive Listing/Descriptions of Workshops, Posters, and Hot Topic Roundtable Conference Sessions are now available ➡️ http://bit.ly/3Ue57Q6.

The workshop committee is pleased to present a dynamic workshop lineup that includes extremely rich and diverse educational content for all disciplines. You will hear from experts who will share the latest research and developments relating to opioid use disorders and treatment. The workshop lineup will include state of the art information on diverse areas of focus such as patient care and best practices, building community partnerships and collaborations, public policy and regulatory changes, workforce development, quality assurance, and financial reimbursement. There will be workshops that focus on emerging treatment trends and developments such as the fentanyl epidemic, mobile opioid treatment programs, regulatory changes, expansion of treatment services in rural areas, integrating treatment with the corrections systems, and integrating harm reduction initiatives. For those newer to the field or those who want a refresher on the basics, we have once again included a “Foundations” track which will include selections on the fundamentals of medication assisted treatment.

The conference will continue to be the world’s premier training and education event for the treatment of opioid use disorders.  We hope to see you in Las Vegas!
#aatod2024 Conference Update. Comprehensive Listing/Descriptions of Workshops, Posters, and Hot Topic Roundtable Conference Sessions are now available ➡️ http://bit.ly/3Ue57Q6. The workshop committee is pleased to present a dynamic workshop lineup that includes extremely rich and diverse educational content for all disciplines. You will hear from experts who will share the latest research and developments relating to opioid use disorders and treatment. The workshop lineup will include state of the art information on diverse areas of focus such as patient care and best practices, building community partnerships and collaborations, public policy and regulatory changes, workforce development, quality assurance, and financial reimbursement. There will be workshops that focus on emerging treatment trends and developments such as the fentanyl epidemic, mobile opioid treatment programs, regulatory changes, expansion of treatment services in rural areas, integrating treatment with the corrections systems, and integrating harm reduction initiatives. For those newer to the field or those who want a refresher on the basics, we have once again included a “Foundations” track which will include selections on the fundamentals of medication assisted treatment. The conference will continue to be the world’s premier training and education event for the treatment of opioid use disorders. We hope to see you in Las Vegas!
3 months ago
View on Instagram |
9/10
Patient access to OTPs saves lives every day.

AATOD has been working with policymakers and regulatory authorities to increase access to opioid treatment programs (OTPs) though the expansion of mobile vans and Medication Assisted Treatment in correctional facilities in the United States. 

Please support AATOD's mission by making an online donation ➡️ https://bit.ly/3uDOeDC #givingtuesday
Patient access to OTPs saves lives every day. AATOD has been working with policymakers and regulatory authorities to increase access to opioid treatment programs (OTPs) though the expansion of mobile vans and Medication Assisted Treatment in correctional facilities in the United States. Please support AATOD's mission by making an online donation ➡️ https://bit.ly/3uDOeDC #givingtuesday
5 months ago
View on Instagram |
10/10

OTPs offer life-saving care beyond methadone services. A recent study found that Hepatitis C virus treatment initiated through OTP telehealth visits resulted in faster adoption of direct-acting antiviral therapy and higher cure rates. Learn more: https://ow.ly/I1NQ50RcE9g

Load More...

#aatod2024 Conference – Las Vegas

COUNTDOWN

2024 Conference

AATOD, Inc.
225 Varick Street, Suite 402
New York, New York 10014

Contact Us
Phone : 212-566-5555
Email : info@aatod.org

Social Sharing
RSS
Follow by Email
Facebook
Twitter
YouTube
LinkedIn
Instagram
Stay Connected to AATOD